The latest update is out from Medistim ASA ( (DE:MD1) ).
Medistim ASA reported an all-time high in quarterly sales revenue, achieving MNOK 151.1, an 11.4% increase compared to the previous year. The company launched the MiraQ INTUI software platform for cardiac surgery and initiated a multicenter study for vascular surgery, highlighting its commitment to innovation. Despite a decline in the APAC region, strong growth was seen in the Americas and EMEA. The company maintains a solid cash position with no interest-bearing debt and proposed a dividend increase, reflecting its robust financial health and strategic market positioning.
More about Medistim ASA
Medistim ASA operates in the global market for cardiac, vascular, and transplant surgery, with its equipment used in approximately 37% of cardiac bypass surgeries worldwide. The company has installed over 3,700 systems across more than 60 countries.
YTD Price Performance: 2.38%
Average Trading Volume: 177
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €239.2M
For an in-depth examination of MD1 stock, go to TipRanks’ Stock Analysis page.